Full-Time

Director of Market Access Spain

Viatris

Viatris

10,001+ employees

Global pharma selling generics and biosimilars

No salary listed

Madrid, Spain

In Person

Based in Madrid, Spain. Occasional travel within Spain and Europe.

Bachelor's

Category
Medical, Clinical & Veterinary (1)

Get referred to Viatris

See people who can refer or advise you

Requirements
  • Advanced degree in life sciences, pharmacy, medicine, health economics, or public health
  • Minimum of 8–10 years of experience in Market Access in Spain, including direct HTA and pricing negotiations
  • Strong technical understanding of HEOR principles, including the ability to interpret and apply health economic models, burden of illness data, and real-world evidence to support pricing and reimbursement submissions
  • Proven track record of leading Market Access strategies for recently launched innovative medicines in Spain
  • Deep knowledge of the Spanish healthcare system, reimbursement pathways, and evolving policy trends
  • Experience managing or mentoring teams and working in a matrix environment
  • Strategic mindset with a hands-on attitude
  • Strong interpersonal, communication, and negotiation skills
  • Fluent in Spanish and English (spoken and written)
  • High level of integrity, ownership, and collaboration
  • Comfortable working in a fast-paced, entrepreneurial environment
  • Willingness to travel nationally and occasionally within Europe
Responsibilities
  • Develop and lead the execution of integrated Market Access strategies for Spain across all therapeutic areas, with a primary focus on innovative and value-added medicines.
  • Lead and coordinate submissions to Spanish HTA and pricing authorities (AEMPS, CIPM, Interministerial Pricing Committee), ensuring compliance and maximizing probability of success.
  • Shape access conditions, pricing corridors, and reimbursement pathways in alignment with business and regional/global objectives.
  • Ensure ongoing ownership of portfolio pricing strategy, including lifecycle price management, mitigation of price erosion in collaboration with the global pricing team.
  • Partner with Medical Affairs, Regulatory, Commercial, Policy, Health Economics, and Global Pricing teams to drive access readiness and evidence generation plans.
  • Serve as the key Market Access representative on launch teams and product-specific steering committees in Spain.
  • Ensure adaptation of core value dossiers and economic models to Spanish requirements.
  • Build and maintain trusted relationships with payer organizations, HTA agencies, policy makers, and healthcare system influencers.
  • In collaboration with Policy team actively contribute to shaping the external access environment to support patient access and business sustainability.
  • Lead and develop the local Market Access function, with direct responsibility for Regional Access activities and oversight of related initiatives across Spain.
  • Contribute to capability building in access, pricing, and health economics across the affiliate.

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Get referred to Viatris

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $3.76 billion, and management raised full-year guidance.
  • Gross leverage fell to 2.9x after repaying $900 million debt in Q2.
  • FDA accepted MR-107A-02, with a December 27, 2026 PDUFA driving new growth.

What critics are saying

  • Nashik fire and FDA Form 483 disruptions cut second-half 2026 revenue by $100 million-$150 million.
  • Tyrvaya rights sale and $177.8 million write-down signal shrinking eye-care ambitions.
  • Novo Nordisk's Wegovy patent fight and generic pricing pressure threaten future margins.

What makes Viatris unique

  • Viatris sells in 165 countries, giving unmatched global reach for generic launches.
  • Greater China execution and e-commerce lifted Q2 2026 growth despite pricing pressure.
  • FDA approval of Gwyn Lo and Effexor Japan expansion broaden branded pipeline.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

18%

1 year growth

18%

2 year growth

18%
Yahoo Finance
Aug 11th, 2026
Viatris beats Q2 estimates with $3.76B revenue, ups full-year guidance amid China growth and margin pressures

Viatris reported second-quarter revenue of $3.76 billion, up 4.9% year-on-year and beating analyst estimates of $3.68 billion. The medication company's non-GAAP earnings per share of $0.69 exceeded forecasts by 15%. CEO Scott Smith attributed the performance to strong commercial execution in Greater China, where investments in established brands and e-commerce drove double-digit growth. Demand for cardiovascular products and higher-margin generics in North America also contributed. The company raised its full-year adjusted EPS guidance to $2.52 at the midpoint, a 5% increase, whilst lifting revenue guidance slightly to $14.75 billion. However, operating margin fell to 0.2% from 6.5% in the prior-year quarter. Management noted supply chain disruptions and lower-margin products in emerging markets as headwinds, alongside manufacturing challenges and policy changes in China.

PR Newswire
Aug 6th, 2026
Viatris reports Q2 revenues of $3.8B, up 5%, raises 2026 guidance despite $119M loss

Viatris reported second-quarter 2026 revenues of $3.8 billion, representing 5% reported growth compared to the same period in 2025. The pharmaceutical company posted a US GAAP net loss of $119 million, primarily driven by a non-cash charge of $177.8 million related to the planned sale of Tyrvaya product rights. Adjusted EBITDA reached $1.2 billion, up 8% operationally year-over-year. The company returned approximately $550 million to shareholders, including roughly $270 million through share repurchases at a weighted average price of $16.42 per share. Viatris reduced its gross leverage ratio to 2.9x after repaying approximately $900 million in debt. The company raised its full-year 2026 financial guidance midpoints across all metrics. In July, Viatris received US FDA approval for Gwyn Lo, a low-dose estrogen contraceptive patch expected to launch later this year.

Yahoo Finance
Aug 2nd, 2026
Viatris wins FDA approval for Gwyn Lo contraceptive patch

Viatris has received US FDA approval for Gwyn Lo, a low-dose estrogen contraceptive patch. The product adds a new branded option to the company's women's health portfolio. Gwyn Lo's approval comes as Viatris shares have shown strong momentum. The stock currently trades at $17.56, reflecting a 40.9% year-to-date return and 107.2% gain over the past year. The contraceptive patch may help diversify Viatris' revenue mix. Investors will be watching how quickly the product gains traction in prescribing patterns and market share. The company's shares trade close to the analyst price target of $17.94. However, Viatris carries a high forward price-to-earnings ratio of 57.84, and its 2.73% dividend yield is reportedly not well covered by earnings.

TipRanks
Jul 1st, 2026
Viatris secures $260M term loan facility to refinance debt and support operations

Viatris has secured a ¥40 billion (approximately $270 million) unsecured term loan facility with a syndicate of lenders led by Mizuho Bank. The three-year facility, which closed on 1 July 2026, will support general corporate purposes and refinance a prior loan of the same amount. The facility is priced at the TIBO Rate plus 1.10%, with pricing linked to Viatris' long-term credit ratings. It includes leverage ratio limits, standard covenants on indebtedness, dividends and mergers, plus default provisions allowing lenders to accelerate repayment. The loan is backed by guarantees from key Viatris subsidiaries and allows penalty-free prepayments, providing the pharmaceutical company with liquidity in the Japanese market whilst maintaining financial flexibility.

Yahoo Finance
Jun 14th, 2026
Viatris raises euro debt to reshape capital structure amid insider selling and growth questions

Viatris has completed a euro-denominated senior unsecured notes offering, adding new capital and euro currency debt to its balance sheet. The global pharmaceutical company, which operates across branded, generic and biosimilar medicines, has not disclosed the size or terms of the transaction. The offering follows recent insider selling and questions about the company's growth trajectory. The fresh capital provides flexibility for future refinancing, acquisitions, divestitures or internal investment decisions. At $16.48, Viatris shares trade 7.9% below the $17.81 analyst target. The stock pays a 2.91% dividend, though analysts have flagged concerns about dividend coverage. Investors will be monitoring how management allocates capital between debt reduction, acquisitions and shareholder returns, particularly given the increased interest costs from the new euro debt.